Sichuan Hebang Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
Sichuan Hebang Biotechnology has a total shareholder equity of CN¥19.4B and total debt of CN¥3.4B, which brings its debt-to-equity ratio to 17.6%. Its total assets and total liabilities are CN¥26.0B and CN¥6.6B respectively. Sichuan Hebang Biotechnology's EBIT is CN¥565.4M making its interest coverage ratio -16.9. It has cash and short-term investments of CN¥2.6B.
Key information
17.6%
Debt to equity ratio
CN¥3.41b
Debt
| Interest coverage ratio | -16.9x |
| Cash | CN¥2.57b |
| Equity | CN¥19.38b |
| Total liabilities | CN¥6.59b |
| Total assets | CN¥25.98b |
Recent financial health updates
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Nov 19
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Recent updates
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Nov 19Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled
Sep 25Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story
Aug 16Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing
Jun 04Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)
May 13Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock
Apr 21Financial Position Analysis
Short Term Liabilities: 603077's short term assets (CN¥10.8B) exceed its short term liabilities (CN¥5.8B).
Long Term Liabilities: 603077's short term assets (CN¥10.8B) exceed its long term liabilities (CN¥832.3M).
Debt to Equity History and Analysis
Debt Level: 603077's net debt to equity ratio (4.4%) is considered satisfactory.
Reducing Debt: 603077's debt to equity ratio has increased from 15.7% to 17.6% over the past 5 years.
Debt Coverage: 603077's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 603077 earns more interest than it pays, so coverage of interest payments is not a concern.